

# **Myostatin Level in CRF Patients With And Without HCV +ve And Its Correlation With BMI**

Thesis

Submitted for Partial Fulfillment of Master Degree  
In Internal Medicine

By

**Heba Mahmoud Ibrahim Elfouly**

(M. B. B. CH)

Under Supervision of

**Prof. Dr. Mohamed Ali Marie Makhoul**

Professor of Internal Medicine

Faculty of Medicine, Ain Shams University

**Dr. Mohammed Magdy Salama**

Lecturer of Internal Medicine

Faculty of Medicine, Ain Shams University

**Dr. Hagar Ahmed Ahmed Elessawy**

Lecturer of Internal Medicine

Faculty of Medicine, Ain Shams University

Faculty of Medicine

Ain Shams University

**2019**



## Acknowledgement

First of all, all my gratitude is to **Allah** almighty – as part of his generous help, throughout my life – for blessing this work, until it has reached its end.

I can hardly find the words to express my gratitude to Prof. **Dr. Mohamed Ali Marie Makhlouf**, Professor of Internal Medicine, Faculty of Medicine, Ain Shams University, for his supervision, continuous help, and encouragement throughout this work, besides the tremendous effort he has done in the revision of the whole work. It is a great honor to work under his guidance and supervision.

I am also indebted to **Dr. Mohammed Magdy Salama**, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University for his guidance, continuous assistance and sincere supervision of this work.

I would like also to express my sincere appreciation and gratitude to **Dr. Hagar Ahmed Ahmed Elessawy**, Lecturer of Internal Medicine, Faculty of Medicine, Ain Shams University for her valuable effort aiding the completion of this work, without which it would have not seen the light.

Last but not least, I dedicate this work to my mother, my husband, my brother and friends, my senior & junior colleagues, including doctors, workers, nurses & medical staff whom without their sincere emotional support, help & pushing me forward, this work would not have ever been completed.

 **Heba Mahmoud Ibrahim Elfouly,**

**2019**

## **List of Contents**

<i><b>Subject</b></i>	<i><b>Page No.</b></i>
<b>List of Abbreviations.....</b>	<b>i</b>
<b>List of Tables.....</b>	<b>iii</b>
<b>List of Figures .....</b>	<b>iv</b>
<b>Introduction .....</b>	<b>1</b>
<b>Aim of the Work.....</b>	<b>3</b>
<b>Review of Literature</b>	
Chronic Renal Disease.....	4
Sarcopenia.....	25
Myostatin .....	59
<b>Patients and Methods.....</b>	<b>72</b>
<b>Results.....</b>	<b>80</b>
<b>Discussion .....</b>	<b>93</b>
<b>Summary .....</b>	<b>101</b>
<b>Conclusion.....</b>	<b>105</b>
<b>Recommendations .....</b>	<b>106</b>
<b>References .....</b>	<b>107</b>
<b>Arabic Summary .....</b>	<b>—</b>

---

## List of Abbreviations

<b>Abbrev.</b>	<b>Full term</b>
<b>CKD</b>	Chronic kidney disease
<b>NDD-CKD</b>	Non-Dialysis Dependent
<b>GFR</b>	Glomerular filtration rate
<b>ESKD</b>	End stage Kidney disease
<b>ROD</b>	Renal Osteodystrophy
<b>HD</b>	Hemodialysis
<b>DHCC</b>	Dihydroxycholecalciferol
<b>HCV</b>	Hepatitis C virus
<b>HOMA-IR</b>	Homeostasis model assessment of insulin resistance
<b>GN</b>	Glomerulonephritis
<b>MPGN</b>	Membranoproliferative glomerulonephritis
<b>MGN</b>	Membranous nephropathy
<b>DOPPS</b>	Dialysis Outcomes and Practice Patterns Study
<b>KDQOL</b>	The Kidney Disease Quality of Life
<b>HO</b>	Hepatic osteodystrophy
<b>IGF-1</b>	Insulin-like growth factor 1
<b>mTOR</b>	Mammalian target of rapamycin
<b>UPP</b>	Ubiquitin–proteasome pathway
<b>GI</b>	Gastrointestinal
<b>BCAAs</b>	Branched chain amino acids
<b>DXA</b>	dual-energy X-ray absorptiometry
<b>CT</b>	Computerized tomography
<b>BMD</b>	Bone mineral density
<b>PTH</b>	Parathyroid hormone
<b>RAAS</b>	Renin angiotensin aldosterone system
<b>LBM</b>	Lean muscle mass
<b>ADL</b>	Activities of daily living
<b>SPPB</b>	Short physical performance battery

<b>MRI</b>	Magnetic resonance imaging
<b>APLM</b>	Appendicular lean mass
<b>CSA</b>	Cross-sectional area
<b>GDF-8</b>	Growth/differentiation factor-8
<b>ALK</b>	Activin-like kinase
<b>mTOR</b>	Mammalian target of rapamycin
<b>GASP-1</b>	GDF-associated serum protein-1
<b>FLRG</b>	Follistatin-related gene

## List of Tables

Table No.	Title	Page No.
<b>Table (1):</b>	Standard dilution.....	76
<b>Table (2):</b>	Comparison between groups according to body mass index. ....	82
<b>Table (3):</b>	Comparison between groups according to skeletal muscle mass index.....	83
<b>Table (4):</b>	Comparison between groups according to Myostatin level. ....	84
<b>Table (5):</b>	Comparison between the two Genders according to Myostatin level. ....	85
<b>Table (6):</b>	Pearson Correlation test between myostatin level and body mass index.....	86
<b>Table (7):</b>	Pearson Correlation test between myostatin level and age. ....	87
<b>Table (8):</b>	Linear Regression test between myostatin level and body mass index.....	88
<b>Table (9):</b>	Pearson correlation between myostatin level and skeletal muscle mass index.....	90
<b>Table (10):</b>	Accuracy of Myostatin level in detection of sarcopenia. ....	91

## List of Figures

Figure No.	Title	Page No.
Figure (1):	Schematic of a nephron .....	6
Figure (2):	Radiograph of both hands showing areas of patchy sclerosis .....	17
Figure (3):	Muscle regulation and potential therapeutic strategies .....	28
Figure (4):	Overview of causes of sarcopenia in cirrhosis .....	30
Figure (5):	The age-related hormonal and metabolic alterations with detrimental effects on skeletal muscle and potentially involved in the development of sarcopenia. GH, Growth hormone .....	35
Figure (6):	Sarcopenia Screening and Staging Outcomes.....	57
Figure (7):	Protein structures for (L-R) pro-TGF- $\beta$ 1, pro-myostatin and pro-activin A .....	61
Figure (8):	Comparison between groups according to body mass index. ....	82
Figure (9):	Comparison between groups according to skeletal muscle mass index. ....	83
Figure (10):	Comparison between groups according to Myostatin level. ....	84
Figure (11):	Comparison between the two Genders according to Myostatin level. ....	85

<b>Figure (12):</b> Pearson Correlation test between myostatin level and body mass index.....	86
<b>Figure (13):</b> Pearson Correlation test between myostatin level and age. ....	87
<b>Figure (14):</b> Linear Regression test between myostatin level and body mass index. ....	89
<b>Figure (15):</b> Correlation between myostatin level and skeletal muscle mass index. ....	90
<b>Figure (16):</b> Accuracy of Myostatin level in detection of sarcopenia.....	92



# Abstract

**Background:** Chronic kidney disease (CKD) is a progressive condition that may negatively affect musculoskeletal health. Secondary sarcopenia due to CKD may be associated with mobility limitations and elevated fall risk. Myostatin is a member of transforming growth factor  $\beta$  family, which regulates synthesis and degradation of skeletal muscle proteins and is associated with the development of sarcopenia.

**Objective:** To evaluate myostatin level in HCV +ve and HCV-ve hemodialysis patients and to study its correlation with body mass index in chronic renal failure patients as compared to matched control group.

**Patients and methods:** All the studied cases were subjected to the following: careful medical history taking, full physical examination, abdominal ultrasonography and laboratory investigations including CBC, liver function tests, renal function tests, Na, K, PO<sub>4</sub> and serum myostatin level.

**Results:** Our results revealed; there is a highly significant increase in the level of myostatin in case of HCV +ve hemodialysis patients; with highly significant statistical difference ( $p < 0.001$ ).

**Conclusion:** Our results revealed; Serum myostatin level is a predictor for the presence of sarcopenia.

---

## Keywords:

Chronic renal failure, sarcopenia, myostatin.

## Introduction

**C**hronic kidney disease (CKD) is a progressive condition that may negatively affect musculoskeletal health. These comorbidities may include malnutrition, osteoporosis and decreased lean body mass. Secondary sarcopenia due to CKD may be associated with mobility limitations and elevated fall risk (**Hernandez et al., 2018**).

Loop diuretic use was associated with increased risk of sarcopenia in patients with NDD-CKD (Non-Dialysis Dependent) (**Ishikawa et al., 2018**).

The classification and staging of sarcopenia includes not only the loss of muscle mass, but also the impact of poor body composition on muscle strength and mobility status (**Cruz-Jentoft et al., 2010**).

Patients with chronic kidney disease are subjected to muscle wasting. Therefore, it is important to investigate surrogate methods that enable the assessment of muscle mass loss in the clinical setting (**Giglio et al., 2018**).

The hemodialysis procedure stimulated protein degradation and reduced protein synthesis. These responses persisted for 2 h following dialysis, suggesting that a process causing protein loss was initiated by the therapy and persisted. Although increasing the intake of protein and

calories improved protein turnover, it did not fully correct the responses to hemodialysis (**Carrero et al., 2013**).

Mid-arm circumference is a simple anthropometric method that reflects the amount of muscle mass by deducting the amount of measured fat in the triceps and bone width. The diagnosis of sarcopenia can be established when this value is below the 10<sup>th</sup> percent mometer and predicts the muscle function (**Duarte-Rojo et al., 2017**)

Myostatin is a member of transforming growth factor  $\beta$  family, which regulates synthesis and degradation of skeletal muscle proteins and is associated with the development of sarcopenia. It is up regulated in the skeletal muscle of chronic kidney disease patients and considered to be involved in the development of uremic sarcopenia. However, serum myostatin levels have rarely been determined and the relationship between myostatin levels with clinical and metabolic factors remain unknown (**Yamada et al., 2016**).

Myostatin regulates the proliferation and differentiation of myoblasts (**Langley et al., 2002**). Moreover, it also controls the activation and proliferation of satellite cells, the stem cells of skeletal muscle (**McCroskery et al., 2003**).

## **Aim of the Work**

Assessment of myostatin level in HCV +ve and HCV -ve hemodialysis patients and to study its correlation with body mass index in chronic renal failure patients as compared to matched control group.

# Chapter I

## Chronic Renal Disease

### **Anatomy and physiology of the kidney:-**

In humans, the kidneys are located high in the abdominal cavity, one on each side of the spine, and lie in a retroperitoneal position at a slightly oblique angle (*Kumar et al., 2014*).

The substance, or parenchyma, of the kidney is divided into two major structures: the outer renal cortex and the inner renal medulla. Grossly, these structures take the shape of eight to 18 cone-shaped renal lobes, each containing renal cortex surrounding a portion of medulla called a renal pyramid (*Walter, 2004*).

The nephron is the microscopic structural and functional unit of the kidney. It is composed of a renal corpuscle and a renal tubule. The renal corpuscle consists of a tuft of capillaries called a glomerulus and an encompassing Bowman's capsule. The renal tubule extends from the capsule. The capsule and tubule are connected and are composed of epithelial cells with a lumen. A healthy adult has 0.8 to 1.5 million nephrons in each kidney (*Bard et al., 2003*).

The renal circulation supplies the blood to the kidneys via the renal arteries, left and right, which branch directly


from the abdominal aorta. Despite their relatively small size, the kidneys receive approximately 20% of the cardiac output (*Walter, 2004*)

The kidneys are central to homeostasis (*Hoenig, and Zeidel, 2014*). Through exquisite sensory mechanisms they regulate blood pressure, water, sodium, potassium, acidity, bone minerals and hemoglobin (*Blaine et al., 2015*), but their core function is the excretion of the waste products of metabolism in urine (*Rayner et al., 2016*)

About 22 % of cardiac output goes to the kidneys and about 20 % of the plasma is filtered, producing about 170 L of glomerular filtrate per day. Ninety-nine percent of this is reabsorbed as it flows along the nephrons so only about 1.5 L of urine is produced per day (*Rayner et al., 2016*).

Filtration occurs through the glomerular filtration barrier (*Pollak et al., 2014*). This is made up of five layers

- The glycocalyx covering the surface of the endothelial cells.
- Holes (fenestrations) in the glomerular endothelial cells.
- The glomerular basement membrane.
- The slit diaphragm between the foot-processes of the podocytes.
- The sub-podocyte space between the slit diaphragm and the podocyte cell body (*Arkill et al., 2014*)



**Figure (1):** Schematic of a nephron (*Linda et al., 2016*)

## Chronic kidney disease:

CKD is defined as:

- Abnormalities of kidney structure or function, present for more than 3 months, with implications for health (NCGC 2014).

Criteria for CKD (any of the following present for more than 3 months):

- Markers of kidney damage (one or more):
- Albuminuria ( $\text{ACR} \geq 3 \text{ mg/mmol}$ ).